Korea Needs ‘More Unified’ Bio-Health Care Policy: Experts
This article was originally published in PharmAsia News
Executive Summary
At a recent seminar in Seoul, South Korean biotechnology and health care experts positively assessed the government's ongoing efforts to nurture the sector, but called for more unified policies and clearer objectives going forward.
You may also be interested in...
Korean Pharma Calls For New Policy ‘Control Tower’, More Support
Amid the recent ousting of President Park Geun-hye amid corruption allegations and a new presidential election only weeks away, the South Korean pharma industry is quickening its calls for policy support from the next administration by recommending a variety of changes.
Korea Govt Partners With J&J To Bring In Local JLABS Site
In collaboration with the national health ministry, J&J’s JLAB program is coming to South Korea as its third destination in Asia, underscoring the country’s increasing need to access multinationals’ know-how and its growing impact on the global biotech landscape and innovation.
Could ASEAN Become Next Priority For Korean Pharma Firms?
Southeast Asia has so far not been a priority market for South Korean pharma firms, largely because of challenges such as access and affordability for patients. But a Deloitte executive suggested at a recent seminar that technology-based medicines, for example using next-generation formulation technologies, could be an initial focus for Korean firms looking to enter the rapidly growing ASEAN grouping.